MA28034A1 - Derives de malonamide bloquant l 'activite gama-secretase - Google Patents
Derives de malonamide bloquant l 'activite gama-secretaseInfo
- Publication number
- MA28034A1 MA28034A1 MA28867A MA28867A MA28034A1 MA 28034 A1 MA28034 A1 MA 28034A1 MA 28867 A MA28867 A MA 28867A MA 28867 A MA28867 A MA 28867A MA 28034 A1 MA28034 A1 MA 28034A1
- Authority
- MA
- Morocco
- Prior art keywords
- lower alkyl
- halogen
- hydrogen
- cycloalkyl
- phenyl
- Prior art date
Links
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical class NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000903 blocking effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- -1 alkyl radical Chemical class 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
DERIVES DE MALONAMIDE BLOQUANT L'ACTIVITE DE LA GAMMA-SECRETASE L'invention concerne des dérivés de malonamide de formule (I), dans laquelle : R1 est un des groupes suivants (formules a) , b), c), d)) ; R2 est un radical alkyle inférieur, alcynyle inférieur, -(CH2)n-O-(alkyle inférieur), -(CH2)n-S-(alkyle inférieur), -(CH2)n-CN, - (CR¿R")n-CF3, - (CR'R")n-CHF2, -(CR'R")n-CH2F, -(CH2)n-C(O)O-(alkyle inférieur), -(CH2)n-halogéno ou est -(CH2)n-cycloalkyle, éventuellement substitué par un ou plusieurs substituants, choisis dans l'ensemble constitué par les halogènes et les radicaux phényle ou CF3 ; R',R" sont, indépendamment de n et l'un de l'autre, l'hydrogène, un radical alkyle inférieur, alcoxy inférieur, un halogène ou un radical hydroxy ; R3, R4 sont indépendamment l'un de l'autre l'hydrogène, un radical alkyle inférieur, alcoxy inférieur, phényle ou un halogène ; R5 est l'hydrogène, un radical alkyle inférieur, -(CH2)n-CF3 ou -(CH2)n-cycloalkyle ; R6 est l'hydrogène ou un halogène ; R7 est l'hydrogène ou un radical alkyle inférieur ; R8 est l'hydrogène, un radical alkyle inférieur, alcynyle inférieur, (CH2)n-CF3, -(CH2)n-cycloalkyle ou -(CH2)n-phényle, éventuellement substitué par un halogène ; R9 est l'hydrogène, un radical alkyle inférieur, -C(O)H, (C(O)-(alkyle inférieur), -C(O)-CF3, -C(O)-CH2F, -C(O)-CHF2, -C(O)-cycloalkyle, -C(O)-(CH2)n-O-(alkyle inférieur), -C(O)O- (CH2)n-cycloalkyle, -C(O)-phényle, éventuellement substitué par un ou plusieurs substituants choisis dans l'ensemble constitué d'un halogène ou de -C(O)O-(alkyle inférieur), ou est -S(O)2-(alkyle inférieur), (S(O)2-CF3, -(CH2)n-cycloalkyle ou est -(CH2)n-phényle, éventuellement substitué par un halogène ; n est 0, 1, 2, 3 ou 4 ; et des sels d'addition d'acide acceptables d'un point de vue pharmaceutique, des énantiomères optiquement; purs, des racémates ou un mélange diastéréoisomérique de ceux-ci. Ces composés peuvent être utilisés pour le traitement d'une maladie d'Alzheimer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03019683 | 2003-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28034A1 true MA28034A1 (fr) | 2006-07-03 |
Family
ID=34224068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28867A MA28034A1 (fr) | 2003-09-09 | 2006-03-10 | Derives de malonamide bloquant l 'activite gama-secretase |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US7160875B2 (fr) |
| EP (1) | EP1711470B1 (fr) |
| JP (2) | JP4571639B2 (fr) |
| KR (3) | KR100838852B1 (fr) |
| CN (1) | CN100593539C (fr) |
| AR (1) | AR045609A1 (fr) |
| AT (1) | ATE428698T1 (fr) |
| AU (1) | AU2004270361B2 (fr) |
| BR (1) | BRPI0413533A (fr) |
| CA (1) | CA2537440C (fr) |
| CO (1) | CO5660268A2 (fr) |
| CR (1) | CR8264A (fr) |
| CY (1) | CY1109225T1 (fr) |
| DE (1) | DE602004020680D1 (fr) |
| DK (1) | DK1711470T3 (fr) |
| EA (1) | EA009940B1 (fr) |
| EC (1) | ECSP066414A (fr) |
| ES (1) | ES2322652T3 (fr) |
| HR (1) | HRP20090266T1 (fr) |
| IL (1) | IL173905A (fr) |
| MA (1) | MA28034A1 (fr) |
| MX (1) | MXPA06002562A (fr) |
| MY (1) | MY141308A (fr) |
| NO (1) | NO20061047L (fr) |
| NZ (1) | NZ545538A (fr) |
| PL (1) | PL1711470T3 (fr) |
| PT (1) | PT1711470E (fr) |
| RS (1) | RS20060146A (fr) |
| SI (1) | SI1711470T1 (fr) |
| TN (1) | TNSN06077A1 (fr) |
| TW (1) | TW200519092A (fr) |
| UA (1) | UA83501C2 (fr) |
| WO (1) | WO2005023772A1 (fr) |
| ZA (1) | ZA200601989B (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1592684B1 (fr) * | 2003-02-04 | 2008-07-30 | F. Hoffmann-La Roche Ag | Derives de malonamide utilises comme inhibiteurs de la gamma-secretase |
| KR100838852B1 (ko) * | 2003-09-09 | 2008-06-16 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| AU2004283803B2 (en) * | 2003-10-06 | 2010-06-24 | F. Hoffmann-La Roche Ag | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors |
| US7211573B2 (en) * | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
| EP2018368B1 (fr) * | 2006-03-27 | 2012-12-05 | F. Hoffmann-La Roche AG | Dérivés de malonamide en tant qu'inhibiteurs de la gamma secrétase |
| BRPI0717587A2 (pt) * | 2006-09-20 | 2013-10-29 | Hoffmann La Roche | Derivados de 4-oxo-2,3,4,5-tetra-hidro-benzo[b][1,4]diazepina |
| BRPI0807341A2 (pt) | 2007-02-02 | 2014-05-20 | Hoffmann La Roche | Derivados de 6-oxo-6,7-di-hidro-5h-dibenzo[b,d]azepin-7-ila |
| MX2009009384A (es) * | 2007-03-15 | 2009-09-14 | Hoffmann La Roche | Malonamidas como antagonistas de orexina. |
| US7579464B2 (en) | 2007-05-25 | 2009-08-25 | Hoffmann-La Roche Inc. | Process for preparation of enantiomerically pure compounds |
| RU2010133489A (ru) * | 2008-01-11 | 2012-02-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Применение ингибиторов гамма-секретазы для лечения рака |
| US8741889B2 (en) | 2008-01-11 | 2014-06-03 | Hoffmann-La Roche Inc | Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor |
| US8309299B2 (en) * | 2010-05-19 | 2012-11-13 | Hoffmann-La Roche Inc. | Combination therapy and method for assessing resistance to treatment |
| WO2012040444A2 (fr) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Traitement de patients présentant un début de maladie d'alzheimer |
| KR101330184B1 (ko) | 2010-10-15 | 2013-11-15 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
| WO2012050370A2 (fr) * | 2010-10-15 | 2012-04-19 | 성균관대학교산학협력단 | Composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif |
| US20120114638A1 (en) | 2010-11-08 | 2012-05-10 | John Boylan | Combination therapy |
| US20120184529A1 (en) | 2011-01-14 | 2012-07-19 | Demario Mark D | Combination therapy |
| US20120225860A1 (en) | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| WO2014047397A1 (fr) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Composés de fluoralkyl- et de fluorocycloalkyl-1,4-benzodiazépinone utilisables en tant qu'inhibiteurs du récepteur notch |
| CN104797569A (zh) | 2012-09-21 | 2015-07-22 | 百时美施贵宝公司 | 取代的1,5-苯并二氮杂*酮化合物 |
| CN104822677A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
| CN105308030A (zh) | 2012-09-21 | 2016-02-03 | 百时美施贵宝公司 | 烷基、氟烷基-1,4-苯并二氮杂*酮化合物 |
| US9249157B2 (en) | 2012-09-21 | 2016-02-02 | Bristol-Myers Squibb Company | Tricyclic heterocycle compounds |
| US9273075B2 (en) | 2012-09-21 | 2016-03-01 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
| CN104854094A (zh) | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | 氟烷基二苯并二氮杂*酮化合物 |
| US9242940B2 (en) | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| JP2016515625A (ja) | 2013-04-04 | 2016-05-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 増殖性疾患を治療するための併用療法 |
| EP2932966A1 (fr) | 2014-04-16 | 2015-10-21 | Novartis AG | Inhibiteurs de la gamma sécrétase pour traiter des maladies respiratoires |
| CN109071450B (zh) * | 2015-10-30 | 2021-06-22 | 帕珀莱恩医疗公司 | 二苯并氮杂卓化合物及其治疗耳部疾病和病症的用途 |
| AU2017376109A1 (en) | 2016-12-16 | 2019-07-11 | Pipeline Therapeutics, Inc. | Methods of treating cochlear synaptopathy |
| EP3615055A1 (fr) | 2017-04-28 | 2020-03-04 | Novartis AG | Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase |
| EP3615068A1 (fr) | 2017-04-28 | 2020-03-04 | Novartis AG | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
| US11161825B2 (en) * | 2017-08-15 | 2021-11-02 | Bayer Aktiengesellschaft | 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides |
| US11492409B2 (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| WO2020261093A1 (fr) | 2019-06-24 | 2020-12-30 | Novartis Ag | Schéma posologique et polythérapies pour des anticorps multispécifiques ciblant un antigène de maturation des lymphocytes b |
| US20230277549A1 (en) * | 2020-07-23 | 2023-09-07 | Purdue Research Foundation | Notch signaling inhibitors for treating obesity and metabolic disorders |
| AU2022339008A1 (en) * | 2021-08-31 | 2024-03-14 | Basf Se | Herbicidal malonamides containing a condensed ring system |
| WO2024096358A1 (fr) | 2022-11-04 | 2024-05-10 | 주식회사 엘지화학 | Support d'enregistrement d'hologramme et élément optique le comprenant |
| CN116621721B (zh) * | 2023-04-12 | 2025-03-18 | 珠海市柏瑞医药科技有限公司 | 一种壬二酰胺的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT675886E (pt) * | 1992-12-10 | 2000-12-29 | Pfizer | Heterociclos nao aromaticos com substituintes aminometileno e sua utilizacao como antagonistas da substancia p |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
| US6632812B2 (en) * | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
| GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| EP1592684B1 (fr) * | 2003-02-04 | 2008-07-30 | F. Hoffmann-La Roche Ag | Derives de malonamide utilises comme inhibiteurs de la gamma-secretase |
| KR100838852B1 (ko) * | 2003-09-09 | 2008-06-16 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
-
2004
- 2004-08-31 KR KR1020077017457A patent/KR100838852B1/ko not_active Expired - Fee Related
- 2004-08-31 JP JP2006525701A patent/JP4571639B2/ja not_active Expired - Lifetime
- 2004-08-31 KR KR1020077017458A patent/KR20070087233A/ko not_active Ceased
- 2004-08-31 DK DK04764665T patent/DK1711470T3/da active
- 2004-08-31 PL PL04764665T patent/PL1711470T3/pl unknown
- 2004-08-31 NZ NZ545538A patent/NZ545538A/en not_active IP Right Cessation
- 2004-08-31 UA UAA200602854A patent/UA83501C2/uk unknown
- 2004-08-31 RS YUP-2006/0146A patent/RS20060146A/sr unknown
- 2004-08-31 BR BRPI0413533-4A patent/BRPI0413533A/pt not_active Application Discontinuation
- 2004-08-31 CN CN200480032641A patent/CN100593539C/zh not_active Expired - Lifetime
- 2004-08-31 PT PT04764665T patent/PT1711470E/pt unknown
- 2004-08-31 EA EA200600503A patent/EA009940B1/ru not_active IP Right Cessation
- 2004-08-31 CA CA2537440A patent/CA2537440C/fr not_active Expired - Fee Related
- 2004-08-31 DE DE602004020680T patent/DE602004020680D1/de not_active Expired - Lifetime
- 2004-08-31 MX MXPA06002562A patent/MXPA06002562A/es active IP Right Grant
- 2004-08-31 EP EP04764665A patent/EP1711470B1/fr not_active Expired - Lifetime
- 2004-08-31 SI SI200431116T patent/SI1711470T1/sl unknown
- 2004-08-31 AU AU2004270361A patent/AU2004270361B2/en not_active Ceased
- 2004-08-31 KR KR1020067004763A patent/KR100834177B1/ko not_active Expired - Fee Related
- 2004-08-31 AT AT04764665T patent/ATE428698T1/de active
- 2004-08-31 HR HR20090266T patent/HRP20090266T1/xx unknown
- 2004-08-31 ES ES04764665T patent/ES2322652T3/es not_active Expired - Lifetime
- 2004-08-31 WO PCT/EP2004/009700 patent/WO2005023772A1/fr not_active Ceased
- 2004-09-02 US US10/933,177 patent/US7160875B2/en not_active Expired - Lifetime
- 2004-09-06 MY MYPI20043603A patent/MY141308A/en unknown
- 2004-09-06 TW TW093126876A patent/TW200519092A/zh unknown
- 2004-09-08 AR ARP040103214A patent/AR045609A1/es not_active Application Discontinuation
-
2006
- 2006-02-23 CO CO06018272A patent/CO5660268A2/es not_active Application Discontinuation
- 2006-02-23 IL IL173905A patent/IL173905A/en active IP Right Grant
- 2006-03-01 CR CR8264A patent/CR8264A/es not_active Application Discontinuation
- 2006-03-03 NO NO20061047A patent/NO20061047L/no not_active Application Discontinuation
- 2006-03-07 EC EC2006006414A patent/ECSP066414A/es unknown
- 2006-03-07 TN TNP2006000077A patent/TNSN06077A1/fr unknown
- 2006-03-08 ZA ZA200601989A patent/ZA200601989B/en unknown
- 2006-03-10 MA MA28867A patent/MA28034A1/fr unknown
-
2009
- 2009-07-10 CY CY20091100729T patent/CY1109225T1/el unknown
-
2010
- 2010-06-18 JP JP2010138970A patent/JP2010229153A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28034A1 (fr) | Derives de malonamide bloquant l 'activite gama-secretase | |
| JP2617546B2 (ja) | ３‐〔４（１‐置換‐４‐ピペラジニル）ブチル〕‐４‐チアゾリジノンおよびその製法 | |
| JPS60209559A (ja) | 置換スルホンアミドベンズアミド及びその製法 | |
| CA2206794A1 (fr) | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament | |
| BE901224A (fr) | Nouveaux derives d'indole utiles comme medicaments et intermediaires et procedes pour leur preparation. | |
| FR2569404A1 (fr) | Nouveaux derives de 1,2-benzisothiazol-3-ylpiperazine, compositions pharmaceutiques contenant de tels composes et leurs procedes de preparation | |
| KR950017993A (ko) | 옥사졸리딘-2-온 유도체 | |
| JP2000504677A (ja) | ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体 | |
| CA2128139A1 (fr) | Agents anti-mdr | |
| FR2462428A1 (fr) | Derives d'acide dithioacyldihydropyrazole carboxylique, derives de dithioacylproline, et composes apparentes, a action antihypertensive | |
| JP2006525990A5 (fr) | ||
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| MX2023003824A (es) | Nuevos compuestos y su uso como sustancias terapeuticamente activas en el tratamiento y/o en la prevencion de las enfermedades que afectan al epitelio pigmentario de la retina. | |
| PH12021551133A1 (en) | N-(4-(oxazol-5-yl)phenyl)chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | |
| MA32019B1 (fr) | Derives d'azetidines, leur preparation et leur application en therapeutique | |
| CS196333B2 (en) | Method of producing/alpha-aminoacetyl/benzene derivatives | |
| MA27492A1 (fr) | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant | |
| FR2636327A1 (fr) | Derives de quinoleine, leurs procedes de preparation et les medicaments les contenant | |
| CA2386417A1 (fr) | Phenyl- et pyridyl-tetrahydropyridines possedant une activite inhibitrice de fnt | |
| WO1991018892A1 (fr) | Derives de benzothiazole, leur preparation et les medicaments les contenant | |
| HU199813B (en) | Process for producing new benzothiazinone derivatives and pharmaceutical compositions comprising such active ingredient | |
| US3984470A (en) | Amidoxime derivatives and process for preparing the same | |
| EP0409692A2 (fr) | Dérivés d'imino-2 hétérocyclylalkyl-3 benzothiazoline, leur préparation et les médicaments les contenant | |
| JPH01102063A (ja) | ジヒドロピリジンエーテル類 | |
| FR2551753A2 (fr) | Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant |